Please try another search
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.
Name | Age | Since | Title |
---|---|---|---|
Molly Harper | 46 | 2021 | Independent Director |
Tamar Thompson | 49 | 2023 | Independent Director |
Charles B O'Keeffe | 84 | 2004 | Lead Independent Director |
Robert D. Fechtner | - | - | Member of Scientific Advisory Board |
Donald A. Denkhaus | 78 | 2015 | Independent Director |
Eugene M. Laska | - | - | Member of Scientific Advisory Board |
Jonathan D. Brodie | - | - | Chairman of Scientific Advisory Board |
Richard B. Silverman | - | 2010 | Member of Scientific Advisory Board |
Patrick J. McEnany | 77 | 2002 | Co-Founder & Chairman |
Richard John Daly | 63 | 2015 | President, CEO & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review